Back to top
more

bluebird bio (BLUE)

(Delayed Data from NSDQ)

$0.94 USD

0.94
4,533,775

-0.03 (-2.72%)

Updated May 28, 2024 04:00 PM ET

After-Market: $0.94 0.00 (-0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth B Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Ryan McQueeney headshot

Why Is Bluebird Bio (BLUE) Stock Gaining Today?

by Ryan McQueeney

Shares of Bluebird Bio (BLUE) gained in morning trading Monday after the company announced a new partnership with Regeneron Pharmaceuticals (REGN). The five-year agreement will see both firms collaborate on new cell therapies for the treatment of cancer.

    bluebird (BLUE) Q2 Loss Wider Than Expected, Revenues Miss

    by Zacks Equity Research

    bluebird (BLUE) incurs Q2 loss on account of higher expenses and lower revenues. Nevertheless, the pipeline progress looks encouraging.

      Bluebird Bio (BLUE) Reports Q2 Loss, Lags Revenue Estimates

      by Zacks Equity Research

      Bluebird (BLUE) delivered earnings and revenue surprises of -26.52% and -28.18%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

        What's in the Cards for Humana (HUM) Stock in Q2 Earnings?

        by Zacks Equity Research

        Humana's (HUM) second quarter is likely to gain traction from solid individual Medicare Advantage membership growth.

          What's in Store for Celldex (CLDX) This Earnings Season?

          by Zacks Equity Research

          With no approved product in Celldex Therapeutics' (CLDX) portfolio, investor focus is expected to be on the company's immuno-oncology pipeline in second-quarter earnings.

            Celgene (CELG) Beats Q2 Earnings & Sales Estimates, Ups View

            by Zacks Equity Research

            Celgene (CELG) reports better-than-expected results for the second-quarter, on the back of growth in Revlimid sales. The company also raises its annual guidance.

              Kevin Cook headshot

              Dopamine and the Weather, Part 2

              by Kevin Cook

              How technology changes human behavior and social rules, but not human nature and genetics???yet.

                Celgene Reports Positive Data on Tecentriq, Abraxane Study

                by Zacks Equity Research

                Celgene (CELG) reports positive results from a late-stage study on the combination of oncology drug, Abraxane, with immuno-oncology drug, Tecentriq, in advanced breast cancer patients.

                  Celgene, Acceleron Report Positive Data on Thalassemia Drug

                  by Zacks Equity Research

                  Celgene (CELG) and partner Acceleron Pharma report positive results on luspatercept from a late-stage study. This is the second positive phase III study for the candidate.

                    Celgene (CELG) Down 21% So Far in 2018: What Lies Ahead?

                    by Zacks Equity Research

                    Celgene's (CELG) shares decline 21%, in the year-to-date period, on pipeline setbacks. However, we expect a better performance in the second half.

                      Celgene Presents Data on CAR T Therapy, Revlimid & Pomalyst

                      by Zacks Equity Research

                      Biotech major Celgene presents encouraging data on its oncology drugs Revlimid, Pomalyst along with other experimental therapies at the ASCO.

                        bluebird's Lenti-D Gets Breakthrough Therapy Status From FDA

                        by Zacks Equity Research

                        bluebird (BLUE) obtained Breakthrough Therapy designation from the FDA for Lenti-D for the treatment of patients with cerebral adrenoleukodystrophy, which should expedite its development.

                          Celgene (CELG) Q1 Earnings & Sales Beat on Revlimid Strength

                          by Zacks Equity Research

                          Celgene (CELG) surpasses both earnings and sales estimates in the first quarter on the back of impressive performance from Pomalyst and Otezla.

                            Can Celgene (CELG) Keep Its Earnings Streak Alive in Q1?

                            by Zacks Equity Research

                            Celgene (CELG) is likely to maintain momentum in the first quarter on the strength of its lead drug, Revlimid despite recent failures.

                              Celgene (CELG) President and COO to Step Down: What's Ahead?

                              by Zacks Equity Research

                              Celgene's (CELG) president and chief operating officer, Scott A. Smith, has decided to step down from his position with immediate effect further adding to the company's woes.

                                Celgene (CELG) Up on Deal With bluebird For CAR-T Candidate

                                by Zacks Equity Research

                                Celgene's (CELG) stock was up by 3% after the company announced a co-promotion agreement with bluebird bio for one of its leading CAR-T candidates.

                                  Zacks Investment Ideas feature highlights: Sarepta Therapeutics, bluebird bio, Editas Medicine, Align Technology and Intellia Therapeutics

                                  by Zacks Equity Research

                                  Zacks Investment Ideas feature highlights: Sarepta Therapeutics, bluebird bio, Editas Medicine, Align Technology and Intellia Therapeutics

                                    Kevin Cook headshot

                                    Why Sarepta (SRPT) Jumped and We Sold

                                    by Kevin Cook

                                    Gains have rewarded the patient, but the long-term is balanced with obstacles still ahead in the FDA gauntlet

                                      Zacks Investment Ideas feature highlights: Sangamo, bluebird, Editas, Sarepta and Juno

                                      by Zacks Equity Research

                                      Zacks Investment Ideas feature highlights: Sangamo, bluebird, Editas, Sarepta and Juno

                                        Kevin Cook headshot

                                        Healthcare Heroes That Aren't Done Yet

                                        by Kevin Cook

                                        Key growth stocks across medical industries tell you the megatrends are in full force for years to come

                                          Zacks Investment Ideas feature highlights: Alibaba, NVIDIA, Edwards Lifesciences, Sangamo Therapeutics and bluebird bio

                                          by Zacks Equity Research

                                          Zacks Investment Ideas feature highlights: Alibaba, NVIDIA, Edwards Lifesciences, Sangamo Therapeutics and bluebird bio

                                            Kevin Cook headshot

                                            Recession is Coming! Not

                                            by Kevin Cook

                                            Even if Dalio is only half right, we can bank on the "melt up" and monitor the data like an interest rate hawk

                                              Celgene (CELG) Q4 Earnings & Sales Beat on Solid Revlimid

                                              by Zacks Equity Research

                                              Celgene's (CELG) fourth-quarter results beat on both sales and earnings driven by solid growth in Revlimid and pick up in Otezla sales after a slowdown.

                                                Bluebird Up on Buyout Speculation After Celgene/Juno Deal

                                                by Zacks Equity Research

                                                Bluebird Bio (BLUE) appears to be solid takeover target, with more and more companies expressing interest in the CAR-T space, especially after Celgene's acquisition of Juno Therapeutics.

                                                  Celgene (CELG) to Acquire Juno Therapeutics for $9 Billion

                                                  by Zacks Equity Research

                                                  Celgene is set to acquire Juno Therapeutics for $87 per share or a total value of $9 billion to strengthen its position in the cellular immunotherapy space.